# SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07662395/  
OnCo record `nct07662395` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial testing SCTB41 in non-small-cell lung cancer, now recruiting.

## Summary

SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer is a phase 2/3 interventional study registered as NCT07662395, led by Sinocelltech, and recruiting on the registry. Official title: A Multicenter Phase II/III Study Evaluating the Efficacy and Safety of SCTB41 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Driver-Negative Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC). Planned enrolment is 410 participants (estimated). The study started in 2026-05-09 and primary completion is expected in 2030-01-24. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT07662395
- Phase: 2/3
- Setting: A Multicenter Phase II/III Study Evaluating the Efficacy and Safety of SCTB41 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Driver-Negative Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Sponsor: Sinocelltech
- Enrolled: 410

## Sources

- ClinicalTrials.gov NCT07662395: https://clinicaltrials.gov/study/NCT07662395

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [SCTB41](https://onco.cc/drugs/sctb41/)
- companies: [Sinocelltech](https://onco.cc/companies/sinocelltech/)

---
JSON: https://onco.cc/api/v1/entities/nct07662395.json